Literature DB >> 15831613

Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction.

J G F Cleland1, A Torabi, N K Khan.   

Abstract

Robust epidemiological data on the incidence of myocardial infarction (MI) are hard to find, but synthesis of data from a number of sources indicates that the average hospital in the UK should admit about two patients with a first MI and one recurrent MI per 1000 population per year. Possibly the most relevant data on the incidence, prevalence, and persistence of post-MI heart failure can be derived from the TRACE study. Most patients will develop heart failure or major left ventricular systolic dysfunction (LVSD) at some time after an MI, most commonly during the index admission. In up to 20% of cases this will be transient, but such patients still have a poor prognosis. There is likely to be around one patient discharged per thousand population per year with heart failure or major LVSD after an acute MI. It is important to organise care structures to ensure that patients with post-MI heart failure and LVSD are identified and managed appropriately.

Entities:  

Mesh:

Year:  2005        PMID: 15831613      PMCID: PMC1876349          DOI: 10.1136/hrt.2005.062026

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  46 in total

1.  Classification of heart failure in population based research: an assessment of six heart failure scores.

Authors:  A Mosterd; J W Deckers; A W Hoes; A Nederpel; A Smeets; D T Linker; D E Grobbee
Journal:  Eur J Epidemiol       Date:  1997-07       Impact factor: 8.082

2.  Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors.

Authors:  W S Aronow; C Ahn; I Kronzon
Journal:  Am J Cardiol       Date:  1997-07-15       Impact factor: 2.778

Review 3.  Anticoagulant and antiplatelet therapy in heart failure.

Authors:  J G Cleland
Journal:  Curr Opin Cardiol       Date:  1997-05       Impact factor: 2.161

4.  Prospective identification of myocardial stunning using technetium-99m sestamibi-based measurements of infarct size.

Authors:  T F Christian; M J Gitter; T D Miller; R J Gibbons
Journal:  J Am Coll Cardiol       Date:  1997-12       Impact factor: 24.094

5.  Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial.

Authors:  M St John Sutton; M A Pfeffer; L Moye; T Plappert; J L Rouleau; G Lamas; J Rouleau; J O Parker; M O Arnold; B Sussex; E Braunwald
Journal:  Circulation       Date:  1997-11-18       Impact factor: 29.690

6.  Importance of congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction.

Authors:  L Køber; C Torp-Pedersen; O D Pedersen; S Høiberg; A J Camm
Journal:  Am J Cardiol       Date:  1996-11-15       Impact factor: 2.778

7.  Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994.

Authors:  W D Rosamond; L E Chambless; A R Folsom; L S Cooper; D E Conwill; L Clegg; C H Wang; G Heiss
Journal:  N Engl J Med       Date:  1998-09-24       Impact factor: 91.245

8.  VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.

Authors:  Eric J Velazquez; Marc A Pfeffer; John V McMurray; Aldo P Maggioni; Jean Lucien Rouleau; Frans Van de Werf; Lars Kober; Harvey D White; Karl Swedberg; Jeffrey D Leimberger; Paul Gallo; Mary Ann Sellers; Susan Edwards; Marc Henis; Robert M Califf
Journal:  Eur J Heart Fail       Date:  2003-08       Impact factor: 15.534

9.  Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation.

Authors:  L Køber; C Torp-Pedersen; S Jørgensen; P Eliasen; A J Camm
Journal:  Am J Cardiol       Date:  1998-06-01       Impact factor: 2.778

10.  Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study.

Authors:  L Køber; C Torp-Pedersen
Journal:  Am J Cardiol       Date:  1995-07-01       Impact factor: 2.778

View more
  23 in total

1.  Silent Myocardial Infarction and Long-Term Risk of Heart Failure: The ARIC Study.

Authors:  Waqas T Qureshi; Zhu-Ming Zhang; Patricia P Chang; Wayne D Rosamond; Dalane W Kitzman; Lynne E Wagenknecht; Elsayed Z Soliman
Journal:  J Am Coll Cardiol       Date:  2018-01-02       Impact factor: 24.094

2.  Heart failure in post-MI patients with persistent IRA occlusion: prevalence, risk factors, and the long-term effect of PCI in the Occluded Artery Trial (OAT).

Authors:  Rahul R Jhaveri; Harmony R Reynolds; Stuart D Katz; Raban Jeger; Elzbieta Zinka; Sandra A Forman; Gervasio A Lamas; Judith S Hochman
Journal:  J Card Fail       Date:  2012-11       Impact factor: 5.712

Review 3.  Heart failure after myocardial infarction: clinical implications and treatment.

Authors:  Marcos F Minicucci; Paula S Azevedo; Bertha F Polegato; Sergio A R Paiva; Leonardo A M Zornoff
Journal:  Clin Cardiol       Date:  2011-06-17       Impact factor: 2.882

4.  Admission glucose and left ventricular systolic function in non-diabetic patients with acute myocardial infarction.

Authors:  Joanna Gierach; Marcin Gierach; Iwona Świątkiewicz; Marek Woźnicki; Grzegorz Grześk; Adam Sukiennik; Marek Koziñski; Jacek Kubica
Journal:  Heart Vessels       Date:  2014-12-25       Impact factor: 2.037

5.  Association of remote ischemic peri-conditioning with reduced incidence of clinical heart failure after primary percutaneous coronary intervention.

Authors:  Adetola Ladejobi; Max Wayne; Christian Martin-Gill; Francis X Guyette; Andrew D Althouse; Michael S Sharbaugh; Steven E Reis; Clifton W Callaway; John A Kellum; A J Conrad Smith; Catalin Toma; Oladipupo Olafiranye
Journal:  Cardiovasc Revasc Med       Date:  2016-12-15

Review 6.  Surgical and physiological challenges in the development of left and right heart failure in rat models.

Authors:  Michael G Katz; Anthony S Fargnoli; Sarah M Gubara; Elena Chepurko; Charles R Bridges; Roger J Hajjar
Journal:  Heart Fail Rev       Date:  2019-09       Impact factor: 4.214

Review 7.  Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction.

Authors:  Carole Nadin
Journal:  Core Evid       Date:  2005-06-30

9.  Monitoring reperfused myocardial infarction with delayed left ventricular systolic dysfunction in rabbits by longitudinal imaging.

Authors:  Yuanbo Feng; Bianca Hemmeryckx; Liesbeth Frederix; Marleen Lox; Jun Wu; Ward Heggermont; Hua Rong Lu; David Gallacher; Raymond Oyen; H Roger Lijnen; Yicheng Ni
Journal:  Quant Imaging Med Surg       Date:  2018-09

10.  Diagnosis and treatment of asymptomatic left ventricular systolic dysfunction after myocardial infarction.

Authors:  Laura Ajello; Giuseppe Coppola; Egle Corrado; Eluisa La Franca; Antonino Rotolo; Pasquale Assennato
Journal:  ISRN Cardiol       Date:  2013-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.